Acurx Pharmaceuticals (NASDAQ:ACXP) Releases Earnings Results, Beats Expectations By $0.02 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) released its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, Zacks reports.

Acurx Pharmaceuticals Trading Down 14.2 %

Acurx Pharmaceuticals stock opened at $0.41 on Wednesday. The stock has a market cap of $7.96 million, a price-to-earnings ratio of -0.37 and a beta of -1.71. The company’s 50-day moving average price is $0.71 and its two-hundred day moving average price is $1.27. Acurx Pharmaceuticals has a 52 week low of $0.40 and a 52 week high of $3.33.

Insider Buying and Selling at Acurx Pharmaceuticals

In related news, CEO David P. Luci bought 49,261 shares of the stock in a transaction on Monday, January 6th. The shares were purchased at an average price of $1.01 per share, with a total value of $49,753.61. Following the purchase, the chief executive officer now owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This represents a 4.70 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 29.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a report on Friday, January 10th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.